Mechanisms of action and therapeutic applications of GLP

Abstract Glucose-dependent insulinotropic polypeptide ( GIP ) and glucagon-like peptide-1 (GLP-1) are two incretins that bind to their respective receptors and activate the downstream signaling in various tissues and organs. Both GIP and GLP-1 play roles in regulating food intake by stimulating neurons in the brain's satiety center. They also stimulate insulin secretion in pancreatic β-cells ...

Incretin hormones are peptides released in the intestine in response to the presence of nutrients in its lumen. The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide ( GIP ). GLP-1 stimulates insulin secretion, inhibits glucagon secretion at pancreatic α cells and has also extrapancreatic influences as slowing of gastric emptying which increases ...
Role of a Dual Glucose

GIP is a 42-amino acid polypeptide secreted from enteroendocrine K-cells that are found in the small intestinal epithelium [24, 25]. It originates from the post-translational processing of pre-pro- GIP and its structure is similar to secretin, glucagon, vasoactive intestinal peptide, and growth hormone-releasing factor [8].
Dual GLP-1/ glucose - dependent insulinotropic polypeptide ( GIP ), dual GLP-1/glucagon (Gcg), and triple GLP-1/ GIP /Gcg agonists have recently emerged and have the potential to transform an already rapidly changing therapeutic landscape. Despite the efficacy of single-target GLP-1 RAs, the glycemic control or weight reduction effects were not universally effective or optimal for all patients. Thus ...

Compounded GLP
The use of glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide ( GIP ) and GLP-1 RA ( GIP /GLP-1 RA) classes has increased substantially over the past several years for treating type 2 diabetes and obesity.
Tirzepatide: a glucose-dependent insulinotropic polypeptide ( GIP ) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes.

List of dual GIPGLP
Dual GIP /GLP-1 receptor agonists, also known as glucose-dependent insulinotropic polypeptide receptors and glucagon-like peptide-1 receptor agonists, are medications that can help reduce appetite and manage blood sugar levels.
The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide ( GIP ). GLP-1 stimulates insulin secretion, inhibits glucagon secretion at pancreatic α cells and has also extrapancreatic influences as slowing of gastric emptying which increases the feeling of satiety.

The dual glucosedependent insulinotropic polypeptide and glucagonlike ...
Dual agonism of glucose-dependent insulinotropic polypeptide ( GIP ) and GLP-1 receptors is a promising new approach currently in clinical development for the treatment of diabetes, obesity, and associated complications. 5 Human genetics has shown protection against coronary heart disease associated with a GLP1R variant, consistent with the ...








The incretin hormones glucose-dependent insulinotropic polypeptide ( GIP ) and glucagon-like peptide-1 (GLP-1) play central roles in metabolic and cardiovascular regulation. GLP-1 receptor agonists (GLP-1RAs) are established therapies for type 2 diabetes mellitus (T2DM) and obesity because of their insulinotropic effects, weight reduction, and proven cardiovascular benefit in trial level. In ...